Aquilo Capital Management
Aquilo Capital Management is an investment firm founded in 2010 and based in San Francisco, California. It operates as a hedge fund manager, utilizing various investment strategies, including long short, fund of funds, and relative value approaches. The firm invests across multiple asset classes, such as fixed income, equities, and derivatives. Additionally, Aquilo Capital Management is involved in funding early-stage companies, reflecting a diversified investment focus.
Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing anticalin-based therapeutics. Anticalins are low molecular-weight proteins derived from lipocalins, which are naturally occurring proteins in the human body. The company’s lead respiratory candidate, PRS-060, is in Phase I trials for asthma and other inflammatory diseases, while its lead immuno-oncology candidate, PRS-343, is also in Phase I trials targeting various cancers. Additionally, Pieris is advancing PRS-080, a treatment for functional iron deficiency in patients with chronic kidney disease, currently in Phase IIa trials, and PRS-344, a bispecific anticalin-antibody fusion protein in preclinical development for oncology. The company collaborates with several partners, including Les Laboratoires Servier, AstraZeneca, and Seattle Genetics, and has research collaborations with academic institutions such as the University of Pittsburgh. Founded in 2000, Pieris Pharmaceuticals aims to address critical medical needs through its innovative drug development approach.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.